ASCO GI 2023 Virtual Poster Presentations

Program Content

Activities

  • Abstract
    Abstract: Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An age stratified analysis.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Metastatic Colorectal Cancer
    Slides: Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: An age-stratified analysis
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Hepatocellular Carcinoma
    Abstract: Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 26, 2023

    Expires: January 25, 2024

  • Hepatocellular Carcinoma
    Slides: Real-world dosing of regorafenib in patients with  unresectable hepatocellular carcinoma (uHCC):  Final analysis of the prospective, observational  REFINE study
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 26, 2023

    Expires: January 25, 2024

  • AGOC
    Abstract: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • AGOC
    Slides: INTEGRATE IIa: Randomised double-blind Phase III  study of regorafenib versus placebo in refractory  advanced Gastro-Oesophageal Cancer (AGOC).
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2023

    Expires: January 24, 2024

  • Metastatic Colorectal Cancer
    Abstract: MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.
    PDF
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2023

    Expires: January 31, 2024

  • Metastatic Colorectal Cancer
    MOUNTAINEER-03 (NCT05253651) is a global, open-label,  randomized, phase 3 study of tucatinib with trastuzumab and  mFOLFOX6 versus standard of care for the first-line treatment of  HER2+ and RAS wild-type mCRC
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 01, 2023

    Expires: January 31, 2024